<code id='39549C5B27'></code><style id='39549C5B27'></style>
    • <acronym id='39549C5B27'></acronym>
      <center id='39549C5B27'><center id='39549C5B27'><tfoot id='39549C5B27'></tfoot></center><abbr id='39549C5B27'><dir id='39549C5B27'><tfoot id='39549C5B27'></tfoot><noframes id='39549C5B27'>

    • <optgroup id='39549C5B27'><strike id='39549C5B27'><sup id='39549C5B27'></sup></strike><code id='39549C5B27'></code></optgroup>
        1. <b id='39549C5B27'><label id='39549C5B27'><select id='39549C5B27'><dt id='39549C5B27'><span id='39549C5B27'></span></dt></select></label></b><u id='39549C5B27'></u>
          <i id='39549C5B27'><strike id='39549C5B27'><tt id='39549C5B27'><pre id='39549C5B27'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:explore    Page View:43
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In